SCHEMBL17837317

SCHEMBL17837317

C=CCOC(=O)C1(CNC(=O)OC(C)(C)C)CN(Cc2ccccc2)CCC1=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPFFR1 Q9GZQ6 6/20 0.45
NPFFR2 Q9Y5X5 6/20 0.45
ALDH1A1 P00352 4/20 0.39
SIGMAR1 Q99720 3/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ACHE P22303 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
FAAH O00519 1/20 0.36
DRD2 P14416 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP1 P29466 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17854730 0.83 NPFFR1 (0.47) NPFFR1NPFFR2ALDH1A1SIGMAR1KMT2A
SCHEMBL4541512 0.76 KDM4E (0.46) ALDH1A1KMT2AL3MBTL1SMN1; SMN2KDM4E
SCHEMBL17837313 0.75 SMN1; SMN2 (0.34) ALDH1A1L3MBTL1SMN1; SMN2DRD2
SCHEMBL17837310 0.74 SMN1; SMN2 (0.34) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL17837305 0.74 SMN1; SMN2 (0.33) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL17837251 0.73 NPC1L1 (0.38) NPFFR1NPFFR2ALDH1A1L3MBTL1FAAH
SCHEMBL17837296 0.73 ALDH1A1 (0.38) NPFFR1NPFFR2ALDH1A1SIGMAR1SMN1; SMN2
SCHEMBL23268368 0.72 NPFFR1 (0.59) NPFFR1NPFFR2ALDH1A1SIGMAR1KMT2A
SCHEMBL2281940 0.72 NPFFR1 (0.59) NPFFR1NPFFR2ALDH1A1SIGMAR1KMT2A
SCHEMBL4511211 0.72 NPFFR1 (0.59) NPFFR1NPFFR2ALDH1A1SIGMAR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377396-B2 Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2022-07-05 US disclosed
US-20200157020-A1 ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2020-05-21 US disclosed
US-10421696-B2 Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2019-09-24 US disclosed
US-20160176773-A1 ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-06-23 US disclosed
US-20160176773-A1 ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-06-23 US disclosed
US-20160176773-A1 ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION CALIFORNIA INSTITUTE OF TECHNOLOGY 2016-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377396-B2 Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation ALG8, MANBA, MAN2A1 NPFFR1 3590/4885NPFFR2 3251/4885ALDH1A1 122/4885
US-10421696-B2 Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation ALG8, MANBA, MAN2A1 NPFFR1 3590/4885NPFFR2 3251/4885ALDH1A1 122/4885
US-20160176773-A1 ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION ALG8, MANBA, MAN2A1 NPFFR1 3627/4885NPFFR2 3325/4885ALDH1A1 156/4885
US-20200157020-A1 ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION ALG8, MANBA, MAN2A1 NPFFR1 3627/4885NPFFR2 3325/4885ALDH1A1 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.